Stockscreener 앱 받기
2.62
1.87%
-0.05
Immunitybio Inc 주식(IBRX)의 최신 뉴스
D. Boral Capital Reiterates "Buy" Rating for ImmunityBio (NASDAQ:IBRX) - MarketBeat
ImmunityBio (NASDAQ:IBRX) Sets New 1-Year LowShould You Sell? - MarketBeat
ImmunityBio (NASDAQ:IBRX) Stock Price Down 5.6%Here's Why - MarketBeat
ImmunityBio: Forging A New Plan After Recent $100 Million Offering - Seeking Alpha
ImmunityBio Shares Plunge After Share Offering - Los Angeles Business Journal
ImmunityBio (NASDAQ:IBRX) Hits New 52-Week LowShould You Sell? - MarketBeat
ImmunityBio: Despite Share Price & Funding Woes Muddy Path To Long-Term Success (IBRX) - Seeking Alpha
ImmunityBio stock plummets on announcing common stock offering - MSN
D. Boral Capital Served as Co-Manager to ImmunityBio, Inc. (Nasdaq: IBRX) in connection with its $100.0 Million Underwritten Public Offering - Yahoo Finance
Form 424B5 ImmunityBio, Inc. - StreetInsider.com
SEC Form 424B5 filed by ImmunityBio Inc. - Quantisnow
ImmunityBio announces proposed public offering of common stock - MSN
ImmunityBio’s Cash Burn And Dilution Dampen Anktiva’s Potential (NASDAQ:IBRX) - Seeking Alpha
ImmunityBio Shares Slide 33% After Public Offering Prices - MarketWatch
What's Going On With ImmunityBio Shares Wednesday? - Benzinga
IMMUNITYBIO INVESTIGATION INITIATED BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Investigates the Officers and Directors of ImmunityBio, Inc.IBRX - The Eastern Progress Online
ImmunityBio, Inc. Announces Pricing of Public Offering of Common Stock - Business Wire
ImmunityBio Shares Down on Plans for Public Offering - MarketWatch
ImmunityBio plans public stock offering By Investing.com - Investing.com Canada
ImmunityBio plans public stock offering - Investing.com India
ImmunityBio, Inc. Announces Proposed Public Offering of Common Stock - Business Wire
Biotech Billionaire Soon-Shiong Sued Over ImmunityBio Stock Move - MSN
More layoffs for ImmunityBio's Dunkirk facility - MSN
ImmunityBio and nCartes Enter Collaboration Agreement on Clinical Trial Data Fulfillment - The Eastern Progress Online
(IBRX) Investment Analysis - Stock Traders Daily
ImmunityBio's (IBRX) Buy Rating Reaffirmed at D. Boral Capital - MarketBeat
Immunitybio Inc. (IBRX): Among the Most Promising Cancer Stocks According to Hedge Funds - Insider Monkey
ImmunityBio and nCartes partner to automate clinical trial data processes - Clinical Trials Arena
Town hopeful after ImmunityBio tour - Evening Observer
Town Hopeful After ImmunityBio Tour - Jamestown Post Journal
ImmunityBio partners with nCartes to streamline trials - Investing.com
ImmunityBio and nCartes Enter Collaboration Agreement on Clinica - GuruFocus.com
ImmunityBio, nCartes announce collaboration on clinical trial data fulfillment - TipRanks
ImmunityBio partners with nCartes to streamline trials By Investing.com - Investing.com UK
ImmunityBio Partners with nCartes to Revolutionize Clinical Trial Data Management | IBRX Stock News - StockTitan
Wall Street Analysts Think ImmunityBio (IBRX) Could Surge 184.43%: Read This Before Placing a Bet - MSN
Immunitybio Inc earnings beat by $0.04, revenue topped estimates - Investing.com Nigeria
ImmunityBio (IBRX) Reports Q3 Loss, Tops Revenue Estimates - MSN
ImmunityBio Completes ANKTIVA’s Post-Approval Enrollment of the 100th Patient in BCG Unresponsive NMIBC CIS Trial and Reports a Complete Response Rate of 71% with a Durable Duration of Response Ranging Up to 54 Months - BioSpace
ImmunityBio announces new data from QUILT 3.032 study - TipRanks
ImmunityBio's Bladder Cancer Drug Shows 71% Response Rate in Key Trial | IBRX Stock News - StockTitan
Following recent decline, ImmunityBio, Inc.'s (NASDAQ:IBRX) top shareholder Chief Scientific Officer Patrick Soon-Shiong sees holdings value drop by 11% - Simply Wall St
ImmunityBio Inc. Reports Earnings Amid Financial Challenges - TipRanks
ImmunityBio Inc (IBRX) Q3 2024 Earnings: GAAP EPS of -$0.12, Rev - GuruFocus.com
ImmunityBio: Q3 Earnings Snapshot - The Pioneer
ImmunityBio Inc. (IBRX) Quarterly 10-Q Report - Quartzy
Innovative Bladder Cancer Therapy Produces $6 Million in Sales - Precision Vaccinations
ImmunityBio, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
2.88%
2.65%
자본화:
|
볼륨(24시간):